INTRODUCTION: Tobacco product testing is a critical component of the Family Smoking Prevention and Tobacco Control Act (FSPTCA), which grants the Food and Drug Administration the authority to regulate tobacco products. The availability of methods and measures that can provide accurate data on the relative health risks across types of tobacco products, brands, and subbrands of tobacco products on the validity of any health claims associated with a product, and on how consumers perceive information on products toxicity or risks is crucial for making decisions on the product's potential impact on public health. These tools are also necessary for making assessments of the impact of new indications for medicinal products (other than cessation) but more importantly of tobacco products that may in the future be marketed as cessation tools. OBJECTIVE: To identify research opportunities to develop empirically based and comprehensive methods and measures for testing tobacco and other nicotine-containing products so that the best science is available when decisions are made about products or policies. METHODS: Literature was reviewed to address sections of the FSPTCA relevant to tobacco product evaluation; research questions were generated and then reviewed by a committee of research experts. RESULTS: A research agenda was developed for tobacco product evaluation in the general areas of toxicity and health risks, abuse liability, consumer perception, and population effects. CONCLUSION: A cohesive, systematic, and comprehensive assessment of tobacco products is important and will require building consensus and addressing some crucial research questions.
INTRODUCTION:Tobacco product testing is a critical component of the Family Smoking Prevention and Tobacco Control Act (FSPTCA), which grants the Food and Drug Administration the authority to regulate tobacco products. The availability of methods and measures that can provide accurate data on the relative health risks across types of tobacco products, brands, and subbrands of tobacco products on the validity of any health claims associated with a product, and on how consumers perceive information on products toxicity or risks is crucial for making decisions on the product's potential impact on public health. These tools are also necessary for making assessments of the impact of new indications for medicinal products (other than cessation) but more importantly of tobacco products that may in the future be marketed as cessation tools. OBJECTIVE: To identify research opportunities to develop empirically based and comprehensive methods and measures for testing tobacco and other nicotine-containing products so that the best science is available when decisions are made about products or policies. METHODS: Literature was reviewed to address sections of the FSPTCA relevant to tobacco product evaluation; research questions were generated and then reviewed by a committee of research experts. RESULTS: A research agenda was developed for tobacco product evaluation in the general areas of toxicity and health risks, abuse liability, consumer perception, and population effects. CONCLUSION: A cohesive, systematic, and comprehensive assessment of tobacco products is important and will require building consensus and addressing some crucial research questions.
Authors: Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller Journal: Tob Control Date: 2010-10 Impact factor: 7.552
Authors: Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Dorothy K Hatsukami; Michael Kotlyar; Louise A Hertsgaard; Yan Zhang; Steven G Carmella; Joni A Jensen; Sharon S Allen; Peter G Shields; Sharon E Murphy; Irina Stepanov; Stephen S Hecht Journal: Addiction Date: 2010-02 Impact factor: 6.526
Authors: David R Strong; Karen Messer; Martha White; Yuyan Shi; Madison Noble; David B Portnoy; Alexander Persoskie; Annette R Kaufman; Kelvin Choi; Charles Carusi; Maansi Bansal-Travers; Andrew Hyland; John Pierce Journal: Addict Behav Date: 2019-01-03 Impact factor: 3.913
Authors: Ramzi G Salloum; Jordan J Louviere; Kayla R Getz; Farahnaz Islam; Dien Anshari; Yoojin Cho; Richard J O'Connor; David Hammond; James F Thrasher Journal: Tob Control Date: 2017-07-13 Impact factor: 6.953
Authors: Dorothy K Hatsukami; Neal L Benowitz; Eric Donny; Jack Henningfield; Mitch Zeller Journal: Nicotine Tob Res Date: 2012-10-25 Impact factor: 4.244
Authors: Kenneth A Perkins; Nicole Kunkle; Joshua L Karelitz; Valerie C Michael; Eric C Donny Journal: Psychopharmacology (Berl) Date: 2016-04-02 Impact factor: 4.530
Authors: Micah L Berman; Warren K Bickel; Andrew C Harris; Mark G LeSage; Richard J O'Connor; Irina Stepanov; Peter G Shields; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2018-09-25 Impact factor: 4.244